| Abstract
Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic
fatty liver disease (NAFLD), antioxidant approaches have not been sufficiently investigated
in human NAFLD management. Resveratrol has been reported to possess a wide range of
biological functions, including antioxidant activities. This study aimed to evaluate the
effects of resveratrol supplementation on oxidative/anti-oxidative status in patients with
NAFLD.
Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted on
60 patients with NAFLD (males and females) aged 20 to 60 years, and body mass index
(BMI) of 25-35 kg/m2. Subjects were randomly assigned to receive a daily dose of 600 mg
resveratrol (2×300 mg pure trans-resveratrol capsules; n=30) or placebo capsules (n=30) for
12 wk. Fasting blood samples, anthropometric measurements, and dietary intakes were
collected for all patients at baseline and at the end of the trial. Oxidative stress was
evaluated by measurement of serum malondialdehyde (MDA), oxidized low-density
lipoprotein (ox-LDL), total antioxidant capacity (TAC), and erythrocyte superoxide
dismutase (SOD) as well as glutathione peroxidase (GSH-Px) activities. Changes in the
outcomes were analyzed using analysis of covariance (ANCOVA).
Results: Resveratrol supplementation did not significantly affect neither serum MDA, ox-
LDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to the placebo
group (All P>0.05). Moreover, changes in serum levels of liver enzymes (ALT, AST, GGT,
and ALP) were not significant in neither of the study groups (All P>0.05).
Conclusion: Resveratrol supplementation did not modify oxidative/anti-oxidative status in
patients with NAFLD. |